Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.
Relmada Therapeutics Stock Plummets Losing 80% Value – Here’s Why
Where Today's News Shapes Tomorrow
